Abstract
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk. GLP-1 is a hormone naturally secreted by the gastrointestinal tract following food intake, playing a critical role in regulating insulin secretion, glucose metabolism, appetite suppression, and gastric motility. FDA approved in December 2017 as Ozempic for type 2 diabetes, and in June 2021 as Wegovy for chronic weight management.
Molecular Background
Semaglutide is structurally similar to human GLP-1 but modified to resist degradation by enzymes such as dipeptidyl peptidase-4 (DPP-4), prolonging its biological activity:
- Extended half-life enables once-weekly subcutaneous dosing
- 94% amino acid sequence homology with native GLP-1
- Acylated with fatty acid chain for albumin binding and reduced renal clearance
- Greater potency than earlier GLP-1 analogs like liraglutide
Mechanism of Action
Semaglutide's primary mechanisms involve multiple physiological pathways:
- GLP-1 Receptor Activation: Increases insulin secretion in response to elevated blood glucose
- Glucagon Suppression: Reduces glucagon release from pancreatic alpha cells
- Gastric Emptying: Slows gastric motility, prolonging satiety
- Hypothalamic Action: Acts directly on appetite-regulation centers in the brain
- Reduced Caloric Intake: Creates lasting feelings of fullness, decreasing hunger signals
Clinical Research Summary
Published clinical trials have demonstrated significant outcomes:
- STEP Trials: Average weight loss of 10-15% of body weight over 68 weeks
- SELECT Trial: 20% reduction in major cardiovascular events
- Glycemic Control: Significant HbA1c reductions in diabetic populations
- Visceral Fat: Substantial reduction in abdominal adipose tissue
Dosing Protocols
- Ozempic (Diabetes): 0.25mg weekly titrated up to 1mg weekly
- Wegovy (Weight Loss): 0.25mg weekly titrated up to 2.4mg weekly
- Administration: Subcutaneous injection once weekly
- Titration Period: Gradual dose escalation over 16-20 weeks
Safety Profile
Common side effects reported in clinical trials:
- Gastrointestinal: Nausea, vomiting, diarrhea, constipation (typically transient)
- Injection Site: Mild local reactions
- "Ozempic Face": Facial volume loss due to rapid weight reduction
Rare but serious considerations:
- Pancreatitis risk (history-dependent)
- Gallbladder disease
- Thyroid C-cell tumors (observed in rodent studies)
- Hypoglycemia when combined with insulin or sulfonylureas
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- History of pancreatitis
- Severe gastrointestinal conditions (gastroparesis, IBD)
- Severe renal impairment
- Pregnancy and breastfeeding
Comparison with Tirzepatide
While semaglutide targets only GLP-1 receptors, tirzepatide is a dual GLP-1/GIP receptor agonist. Clinical trials suggest tirzepatide may offer enhanced weight loss, though semaglutide has a more extensively documented safety and efficacy profile to date.
Current Research Status
Semaglutide is FDA-approved for both type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Ongoing research continues to explore its effects on cardiovascular outcomes, non-alcoholic steatohepatitis (NASH), and combination therapies with other metabolic peptides.